参考来源: Dzienis M, Cundom J, Fuentes CS, et al. Pembrolizumab plus carboplatin and paclitaxel as first-line therapy for recurrent/metastatic head and neck squamous cell carcinoma (KEYNOTE-B10): a single-arm phase IV trial. J Clin Oncol. Published online July 22, 2024. doi:10.1200/JCO....
There were no new safety signals.#Pembrolizumab plus carboplatin and paclitaxel showed promising antitumor activity and a manageable safety profile in first-line R/M HNSCC, suggesting this combination may be an alternative option for this patient population.Marcin Dzienis...
Pembrolizumab(200毫克静脉注射)加上研究者选择的四种铂类化疗方案之一:paclitaxel(175毫克/米2)加cisplatin(50毫克/米2),加或不加贝伐单抗(15毫克/公斤);或paclitaxel(175毫克/米2)加carboplatin曲线下面积(AUC)5,加或不加贝伐单抗(15毫克/公斤),每21天周期的第1天,最多35周期(最长约两年);或 安慰剂加研究者...
1.Eskander RN, Sill MW, Beffa L, et al. SEMINAL: Pembrolizumab versus placebo in addition to carboplatin and paclitaxel for measurable stage III or IVA, stage IVB, or recurrent endometrial cancer: the phase 3, NRG GY018 study. 2023 Annual Global Meeting of theInternationalGynecologic Cancer So...
Carboplatin/paclitaxel/pembrolizumab. Reactions Weekly 1923, 127 (2022). https://doi.org/10.1007/s40278-022-22990-2 Download citation Published10 September 2022 Issue DateSeptember 2022 DOIhttps://doi.org/10.1007/s40278-022-22990-2 Access this article Log in via an institution Buy article PDF...
Carboplatin/paclitaxel/pembrolizumab. Reactions Weekly 1955, 121 (2023). https://doi.org/10.1007/s40278-023-38368-3 Download citation Published06 May 2023 Issue DateMay 2023 DOIhttps://doi.org/10.1007/s40278-023-38368-3 Access this article Log in via an institution Subscribe and save Springer...
13、 (i) Rao RD, Holtan SG, Ingle JN, et al. Combination of paclitaxel and carboplatin as second-line therapy for patients with metastatic melanoma. Cancer. 2006;106(2):375-382. (ii) Agarwala SS, Keilholz U, Hogg D, et al. Randomized phase III study of paclitaxel plus carboplatin ...
近日,默沙东(MSD)宣布其关键3期临床试验KEYNOTE-407在早期参与者队列的中期分析中抵达了预先指定的总体缓解率(ORR)的次要终点,该研究是评估默沙东的PD-1抗体Keytruda(pembrolizumab)与卡铂—紫杉醇(carboplatin-paclitaxel)或蛋白结合型紫杉醇(nab-paclitaxel)联合一线治疗转移性鳞状非小细胞肺癌(sNSCLC)的疗效。560例未经...
Food and Drug Administration (FDA) has approved KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with carboplatin and paclitaxel, followed by KEYTRUDA as a single agent, for the treatment of adult patients with primary advanced or rec...
A phase 2clinical trialincluded 540 patients with metastaticmelanomarefractory toipilimumab. These patients were randomized 1:1:1 to receivepembrolizumab2mg/kg every 3 weeks, 10mg/kg every 3 weeks, or chemotherapy chosen by the investigator (carboplatin+paclitaxel,carboplatin, paclitaxel,dacarbazine, or...